Ownership Summary
A total of 8 institutions have reported a stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) as of December 2025, according to recent 13F filings with the SEC.
- Bluejay Diagnostics saw its institutional ownership percentage rose to 42.6% in December 2025 from 23.7% in September 2025.
- The company experienced a 3676.50% quarterly change in institutional shares held, alongside an increase of 60.00% in total owners annually.
- During the quarter, 7 institutions bought more Bluejay Diagnostics shares, 1 sold shares, and 0 of the 8 total investors held their position steady.
- Collectively, institutional investors increased their stake in Bluejay Diagnostics to 168.43K shares as of December 2025, a change that is up by 163.97K shares quarter on quarter and up 165.93K shares year over year.
- The top institutional stake in Bluejay Diagnostics as of December 31, 2025 belongs to ARMISTICE CAPITAL, LLC, which owns 65.00K shares, or 16.44% of the company.
- Among the most significant buyers of Bluejay Diagnostics during December 2025 were ARMISTICE CAPITAL, LLC (65.00K), CITADEL ADVISORS LLC (41.79K), RENAISSANCE TECHNOLOGIES LLC (32.10K), TWO SIGMA SECURITIES, LLC (14.35K), GEODE CAPITAL MANAGEMENT, LLC (10.26K).
- Leading sellers of Bluejay Diagnostics stock in December 2025 included Tower Research Capital LLC (TRC) (15).
- The top 8 institutional holders of Bluejay Diagnostics for the quarter ending December 2025 included ARMISTICE CAPITAL, LLC (65.00K), CITADEL ADVISORS LLC (41.79K), RENAISSANCE TECHNOLOGIES LLC (32.10K), TWO SIGMA SECURITIES, LLC (14.35K), GEODE CAPITAL MANAGEMENT, LLC (10.26K), Tower Research Capital LLC (TRC) (4.43K), L1 Global Manager Pty Ltd (483), BANK OF AMERICA CORP /DE/ (15).